NGM Key Statistics, Chart & Performance
The current stock price of NGM is 1.54 USD. In the past month the price increased by 1.32%. In the past year, price decreased by -59.79%.
NGM Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NGM. When comparing the yearly performance of all stocks, NGM is a bad performer in the overall market: 85.63% of all stocks are doing better.
NGM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NGM. While NGM has a great health rating, there are worries on its profitability.
NGM Financial Highlights
Over the last trailing twelve months NGM reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS increased by 16.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.31% | ||
| ROE | -95.79% | ||
| Debt/Equity | 0 |
NGM Forecast & Estimates
11 analysts have analysed NGM and the average price target is 1.7 USD. This implies a price increase of 10.11% is expected in the next year compared to the current price of 1.54.
For the next year, analysts expect an EPS growth of 29.44% and a revenue growth -100% for NGM
NGM Ownership
NGM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.05 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 21 | 525.25B | ||
| MRK | MERCK & CO. INC. | 12.61 | 275.78B | ||
| PFE | PFIZER INC | 8.09 | 147.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.31 | 110.95B | ||
| ZTS | ZOETIS INC | 19.73 | 55.12B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.66 | 22.93B | ||
| VTRS | VIATRIS INC | 5.6 | 15.03B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.31 | 12.07B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.55B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.69B |
Related stock screener links
About NGM
Company Profile
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company is headquartered in South San Francisco, California and currently employs 239 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need. The Company’s portfolio of product candidates includes NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin, NGM936 and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). The firm's NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.
Company Info
NGM BIOPHARMACEUTICALS INC
333 Oyster Point Blvd
South San Francisco CALIFORNIA 94080 US
CEO: David J. Woodhouse
Employees: 239
Phone: 16502435555
NGM BIOPHARMACEUTICALS INC / NGM FAQ
What does NGM BIOPHARMACEUTICALS INC do?
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company is headquartered in South San Francisco, California and currently employs 239 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need. The Company’s portfolio of product candidates includes NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin, NGM936 and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). The firm's NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.
What is the current price of NGM stock?
The current stock price of NGM is 1.54 USD. The price decreased by -1.28% in the last trading session.
Does NGM BIOPHARMACEUTICALS INC pay dividends?
NGM does not pay a dividend.
What is the ChartMill technical and fundamental rating of NGM stock?
NGM has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for NGM stock?
NGM BIOPHARMACEUTICALS INC (NGM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
Who owns NGM BIOPHARMACEUTICALS INC?
You can find the ownership structure of NGM BIOPHARMACEUTICALS INC (NGM) on the Ownership tab.